Sex and gender—biological and social constructs—significantly impact the prevalence of
protective and risk factors, influencing the burden of Alzheimer's disease (AD; amyloid beta …

Sex or gender differences in the risk of Alzheimer's disease and related dementias (ADRD)
differ by world region, suggesting that there are potentially modifiable risk factors for …

Early detection of cis phosphorylated tau (cis P-tau) may help as an effective treatment to
control the progression of Alzheimer's disease (AD). Recently, we introduced for the first time …

Background An aging society has increased rates of late onset Alzheimer disease dementia
(ADD), the most common form of age-related dementia. This neurodegenerative disease …

INTRODUCTION Accumulating evidence indicates disproportionate tau burden and tau‐
related clinical progression in females. However, sex differences in plasma phosphorylated …

Background Olfactory identification dysfunction frequently occurs in individuals with
cognitive decline; however, a pathological mechanism linking the two has not been …

Introduction Females may have greater susceptibility to Alzheimer's disease (AD)‐
pathology. We examined the effect of sex on pathology, neurodegeneration, and memory in …

Amyloid-β (A β) is the target in many clinical trials for Alzheimer's disease (AD). Preclinical
AD patients are heterogeneous with regards to different backgrounds and diagnosis …

Background: Olfactory identification (OI) impairment appears early in the course of
Alzheimer's disease dementia (AD), prior to detectable cognitive impairment. However, the …

Background: Growing evidence suggests that there may be a sex-specific biological risk for
Alzheimer's disease (AD). Individuals with autosomal dominant AD due to a mutation …